Dr. Jennifer L Jebrock is a pharmacist who is specialized in Pharmacotherapy in Miami, Florida. Patients can reach her at 1611 Nw 12th Ave, Pharmacy Services, B069, Miami or contact her on 305-585-7350. Active license number of Dr. Jennifer L Jebrock is PS42794 for Pharmacotherapy in Florida. Dr. Jennifer L Jebrock is a licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing pharmacotherapeutic care of patients, by developing, implementing, monitoring, and modifying complex treatment plans, providing advanced level education and consultation, and collaborating with other health professionals in the management of therapy.
Complete Profile:
Dr. Jennifer L Jebrock speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. Jennifer L Jebrock are as mentioned below.
NPI Number:
1144456252
NPI Enumeration Date:
03 Jun, 2009
NPI Last Update On:
03 Jun, 2009
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Jennifer L Jebrock are as mentioned below.
Specialization
License Number
State
Status
Pharmacotherapy
PS42794
Florida
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1343 Sw 4th Ct, Fort Lauderdale, Florida
Zip:
33312-7521
Phone Number:
305-585-7350
Fax Number:
305-585-7412
Patients can reach Dr. Jennifer L Jebrock at 1611 Nw 12th Ave, Pharmacy Services, B069, Miami, Florida or can call on phone at 305-585-7350.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 December, 2024.